Clearside Biomedical Files 8-K

Ticker: CLSDQ · Form: 8-K · Filed: Dec 12, 2024 · CIK: 1539029

Clearside Biomedical, Inc. 8-K Filing Summary
FieldDetail
CompanyClearside Biomedical, Inc. (CLSDQ)
Form Type8-K
Filed DateDec 12, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: disclosure, 8-K

TL;DR

Clearside Biomedical dropped an 8-K, check it for updates.

AI Summary

Clearside Biomedical, Inc. filed an 8-K on December 12, 2024, to report on various events. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. Specific details regarding the nature of these events or any associated financial figures were not provided in the excerpt.

Why It Matters

This 8-K filing indicates that Clearside Biomedical is disclosing material information to the public, which could impact investor understanding of the company's current status.

Risk Assessment

Risk Level: low — The filing is a standard disclosure form and does not inherently indicate significant risk without further details on the reported events.

Key Players & Entities

  • Clearside Biomedical, Inc. (company) — Registrant
  • December 12, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of Incorporation
  • Alpharetta, Georgia (location) — Principal Executive Offices

FAQ

What specific events are being disclosed in this 8-K filing?

The filing indicates disclosures related to Regulation FD, Other Events, and Financial Statements and Exhibits, but the specific details of these events are not provided in the excerpt.

When was this 8-K report filed?

The report was filed on December 12, 2024.

What is the principal business address of Clearside Biomedical, Inc.?

The principal executive offices are located at 900 North Point Parkway, Suite 200, Alpharetta, Georgia 30005.

Under which section of the Securities Exchange Act is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is the Commission File Number for Clearside Biomedical, Inc.?

The Commission File Number is 001-37783.

Filing Stats: 579 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-12-12 16:30:19

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Mar

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 12, 2024, Clearside Biomedical, Inc. (the " Company ") updated its corporate presentation for use in meetings with investors, analysts and others. The presentation is available through the Company's website and a copy is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act ") or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this item of this report.

01 Other Events

Item 8.01 Other Events. As disclosed above, on December 12, 2024 the Company updated its corporate presentation, which is attached as Exhibit 99.1 hereto. The information on slides 31 through 37 of Exhibit 99.1 is incorporated by reference herein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Corporate Presentation 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Clearside Biomedical, Inc. By: /s/ Charles A. Deignan Date: December 12, 2024 Charles A. Deignan Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.